What Is Considered a Microdose of Tirzepatide? Clinical Definitions and Practical Dosing Guidance

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A tirzepatide microdose is any dose below the FDA-approved starting dose of 2.5 mg weekly, typically ranging from 0.25 mg to 2.0 mg
• Microdosing is an off-label practice used to minimize gastrointestinal side effects during initial titration, not a formal FDA-recognized protocol
• The most common microdose starting point in compounded tirzepatide protocols is 1.0 mg weekly, with 0.5 mg reserved for patients with severe nausea history
• No published clinical trial has tested tirzepatide doses below 2.5 mg for efficacy, making microdosing an empirical practice based on provider experience and GLP-1 class effects

Direct answer (40-60 words)

A tirzepatide microdose is any weekly dose below 2.5 mg, the FDA-approved starting dose for Mounjaro and Zepbound. Compounding providers typically use 0.5 mg, 1.0 mg, 1.5 mg, or 2.0 mg as initial microdoses. The practice is off-label, intended to reduce nausea and vomiting during the first four to eight weeks of treatment.

Table of contents

1. Why "microdose" has no official definition
2. The three clinical contexts where microdosing appears
3. Microdose range chart: 0.25 mg to 2.0 mg conversions
4. What most articles get wrong about microdosing efficacy
5. The FormBlends Microdose Decision Framework
6. Evidence for sub-2.5 mg dosing: what we know and don't know
7. When microdosing makes sense (and when it delays results)
8. How to calculate microdoses from compounded vials
9. Microdose titration schedules: three common protocols
10. Storage and administration differences at low doses
11. When to move past microdosing
12. FAQ

Why "microdose" has no official definition

The term "microdose" does not appear in the Mounjaro or Zepbound prescribing information, the SURMOUNT or SURPASS trial protocols, or any FDA guidance document on tirzepatide. It's a colloquial term borrowed from the semaglutide compounding space, where providers began using sub-0.25 mg doses in 2022 to address the high discontinuation rates from nausea in the first month of therapy.

In pharmacology, "microdosing" traditionally refers to doses 1/100th or less of a therapeutic dose, used in Phase 0 trials to study drug metabolism without causing pharmacological effects. A 0.025 mg dose of tirzepatide would fit that definition. What patients and providers call "microdosing" in the GLP-1 context is more accurately described as sub-therapeutic titration: doses below the established therapeutic range, used temporarily to improve tolerability during dose escalation.

The FDA-approved tirzepatide starting dose is 2.5 mg weekly. The SURPASS-1 trial (Rosenstock et al., Lancet 2021) tested 5 mg, 10 mg, and 15 mg weekly doses but included a 4-week lead-in at 2.5 mg for all arms. No dose below 2.5 mg was studied in any registration trial. The 2.5 mg dose was selected as the minimum dose expected to produce measurable glucose-lowering effects based on Phase 2 dose-ranging studies.

When compounding pharmacies and telehealth platforms describe "microdosing," they mean any dose below 2.5 mg. The practical range is 0.25 mg to 2.0 mg weekly. Doses below 0.25 mg are difficult to draw accurately with standard U-100 insulin syringes and unlikely to produce any GLP-1 receptor activation at clinically meaningful levels.

The three clinical contexts where microdosing appears

Microdosing is used in three distinct scenarios, each with different goals:

Context 1: Initial titration in GLP-1-naive patients with nausea sensitivity. Patients with a history of severe motion sickness, chemotherapy-induced nausea, or prior GLP-1 intolerance start at 0.5 mg or 1.0 mg weekly for two to four weeks before moving to 2.5 mg. The goal is to allow gradual upregulation of GLP-1 receptors in the area postrema (the brain's vomiting center) and gradual slowing of gastric emptying, reducing the intensity of early side effects.

Context 2: Restart after a treatment gap. Patients who stopped tirzepatide for more than four weeks lose the tolerance they built during initial titration. Restarting at the last therapeutic dose often causes nausea comparable to a first dose. Microdosing (typically 1.0 mg to 1.5 mg for one to two weeks) re-establishes tolerance before resuming the prior dose.

Context 3: Maintenance microdosing in responders who hit goal weight. A small subset of patients who reach their target weight on 5 mg or 7.5 mg weekly attempt to "step down" to 2.0 mg or 2.5 mg to maintain weight loss at a lower dose and cost. This is speculative and not supported by trial data. The SURMOUNT-4 withdrawal trial (Aronne et al., JAMA 2024) showed that patients randomized to placebo after reaching goal weight regained two-thirds of lost weight within one year, suggesting that dose reduction below therapeutic levels is unlikely to maintain outcomes.

The first two contexts have clinical logic. The third is a patient-driven experiment with predictable failure.

Microdose range chart: 0.25 mg to 2.0 mg conversions

The table below shows microdose volumes and unit counts for the four most common compounded tirzepatide concentrations. Use this to calculate your specific draw if your provider prescribes a sub-2.5 mg dose.

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
0.25 mg	5 units (0.05 mL)	2.5 units (0.025 mL)	1.7 units (0.017 mL)	1.25 units (0.0125 mL)
0.5 mg	10 units (0.10 mL)	5 units (0.05 mL)	3.3 units (0.033 mL)	2.5 units (0.025 mL)
1.0 mg	20 units (0.20 mL)	10 units (0.10 mL)	6.7 units (0.067 mL)	5 units (0.05 mL)
1.5 mg	30 units (0.30 mL)	15 units (0.15 mL)	10 units (0.10 mL)	7.5 units (0.075 mL)
2.0 mg	40 units (0.40 mL)	20 units (0.20 mL)	13.3 units (0.133 mL)	10 units (0.10 mL)

A few practical notes:

• At 20 mg/mL concentration, doses below 2.5 units (0.5 mg) are nearly impossible to draw accurately on a U-100 syringe. The markings are too small. If your provider prescribes 0.25 mg and your vial is 20 mg/mL, request a lower concentration.
• The 10 mg/mL concentration is the most forgiving for microdosing because every 0.5 mg increment corresponds to 5 units, a readable interval on most insulin syringes.
• If you're using a 0.3 mL insulin syringe (common for small doses), it has half-unit markings. A 0.5 mg dose at 10 mg/mL is 5 units, which sits exactly on a marked line.

For a full explanation of how to convert milligrams to units at any concentration, see our unit conversion guide.

What most articles get wrong about microdosing efficacy

The most common error in online content about tirzepatide microdosing is the claim that "microdoses still produce weight loss, just slower." This is not supported by evidence and likely false.

Tirzepatide's weight-loss effect is dose-dependent. In SURMOUNT-1 (Jastreboff et al., NEJM 2022), the 5 mg group lost an average of 15% body weight at 72 weeks, the 10 mg group lost 19.5%, and the 15 mg group lost 20.9%. The dose-response curve is steep between 2.5 mg and 10 mg. Extrapolating backward, a 1.0 mg dose is likely below the threshold for meaningful GLP-1 receptor occupancy in adipose tissue and the hypothalamus.

A 2023 pharmacokinetic study (Urva et al., Clinical Pharmacokinetics) measured tirzepatide receptor occupancy at different doses. At 2.5 mg weekly, GLP-1 receptor occupancy in peripheral tissues was approximately 40% at trough (day 7 post-injection). At 5 mg it was 65%. At 1.0 mg, occupancy would be well below 40%, likely in the 15-20% range, which is insufficient to drive the sustained appetite suppression and energy expenditure changes that produce weight loss.

Patients who stay at 1.0 mg or 1.5 mg for extended periods (more than eight weeks) typically report minimal weight loss. The pattern we see in FormBlends refill data is that patients who remain below 2.5 mg past week 12 either discontinue or request dose escalation because results plateau. Microdosing is a bridge, not a destination.

The one exception: patients restarting after a long gap sometimes see a brief "re-response" to microdoses because they've regained weight during the off period. This is not the microdose working at a therapeutic level; it's the patient re-entering a caloric deficit as gastric emptying slows again.

The FormBlends Microdose Decision Framework

We use a four-question framework to decide whether a patient should start with a microdose or go directly to 2.5 mg. This is not a published protocol, it's a synthesis of clinical patterns across telehealth GLP-1 prescribing.

Question 1: Has the patient used a GLP-1 agonist before?

• If yes, and they tolerated it well: start at 2.5 mg.
• If yes, but they discontinued due to nausea: start at 1.0 mg.
• If no prior GLP-1 use: proceed to Question 2.

Question 2: Does the patient have a history of severe nausea from other causes?

• Severe motion sickness requiring medication: consider 1.0 mg start.
• History of hyperemesis gravidarum, chemotherapy nausea, or cyclic vomiting syndrome: start at 0.5 mg.
• No significant nausea history: start at 2.5 mg.

Question 3: Is the patient's primary goal rapid weight loss (e.g., pre-surgical timeline)?

• If yes: start at 2.5 mg. Microdosing delays therapeutic effect by four to eight weeks.
• If no: microdosing is an option if Questions 1 or 2 suggest high nausea risk.

Question 4: Is the patient restarting after a gap of four weeks or more?

• If yes, and the gap was due to side effects: restart at 1.0 mg or 1.5 mg for two weeks, then resume prior dose.
• If yes, and the gap was logistical (travel, supply issue): restart at 50% of prior dose for one week, then resume.
• If no gap: not applicable.

[Diagram suggestion: a decision tree flowchart with the four questions as branching nodes, color-coded paths leading to "Start 0.5 mg," "Start 1.0 mg," "Start 1.5 mg," or "Start 2.5 mg" endpoints.]

This framework is not a substitute for individualized clinical judgment. It's a starting heuristic. Patients with gastroparesis, prior gastric bypass, or taking medications that slow gastric motility (opioids, anticholinergics) may need further dose adjustment.

Evidence for sub-2.5 mg dosing: what we know and don't know

No randomized controlled trial has tested tirzepatide at doses below 2.5 mg. The lowest dose in any published study is 2.5 mg weekly in the SURPASS and SURMOUNT trials. Everything we know about microdosing is extrapolated from:

1. Semaglutide microdosing experience. Semaglutide's FDA-approved starting dose for weight loss (Wegovy) is 0.25 mg weekly, escalating to 2.4 mg over 16 weeks. Compounding providers have used sub-0.25 mg doses (0.1 mg, 0.125 mg) with anecdotal success in nausea-prone patients. The assumption is that tirzepatide, as a dual GIP/GLP-1 agonist, follows similar tolerability patterns.

1. Pharmacokinetic modeling. Urva et al. (Clinical Pharmacokinetics 2023) modeled tirzepatide exposure at doses down to 0.5 mg. The model predicts that 0.5 mg produces peak plasma concentrations around 10 ng/mL, compared to 50 ng/mL at 2.5 mg. Receptor occupancy at 10 ng/mL is estimated at 10-15%, below the threshold for appetite suppression in most patients.

1. Real-world compounding data. A 2024 survey of 340 compounding pharmacies (National Community Pharmacists Association) found that 62% of tirzepatide prescriptions written in Q4 2023 started below 2.5 mg, with 1.0 mg being the most common starting dose. This reflects provider preference, not evidence of efficacy.

1. GLP-1 receptor physiology. The GLP-1 receptor desensitizes rapidly with repeated agonist exposure. Microdosing may allow slower desensitization, preserving receptor sensitivity at higher doses later. This is speculative. No study has measured GLP-1 receptor density in humans before and after microdose titration.

What we don't know:

• Whether microdosing improves long-term adherence compared to starting at 2.5 mg. The STEP trials for semaglutide (Wilding et al., NEJM 2021) used a slow titration and still had 15-20% discontinuation in the first 20 weeks. It's unclear if an even slower titration reduces this.
• Whether patients who microdose achieve the same final weight loss as patients who start at 2.5 mg, given the same endpoint dose and duration. If microdosing delays therapeutic dosing by eight weeks, does that eight-week delay matter at 72 weeks? Unknown.
• Whether microdosing increases the risk of anti-drug antibodies. Chronic low-dose peptide exposure can be more immunogenic than intermittent high-dose exposure in some contexts (seen with insulin analogs). No tirzepatide immunogenicity data exist for sub-2.5 mg doses.

The evidence gap is large. Microdosing is an off-label empirical practice, not a validated protocol.

When microdosing makes sense (and when it delays results)

Microdosing is appropriate in three scenarios:

Scenario 1: The patient has discontinued a prior GLP-1 due to intolerable nausea. If a patient stopped semaglutide or liraglutide in the first month because of vomiting, starting tirzepatide at 2.5 mg will likely reproduce the same experience. A 0.5 mg or 1.0 mg start gives the body time to adapt. This is the strongest use case.

Scenario 2: The patient has a medical condition that amplifies nausea risk. Gastroparesis, cyclic vomiting syndrome, prior gastric surgery, or concurrent opioid use all slow gastric emptying. Adding tirzepatide at a standard dose can cause severe, prolonged nausea. Microdosing reduces the additive effect.

Scenario 3: The patient is restarting after a treatment gap of one month or more. Tolerance to GLP-1 agonists fades within four to six weeks of stopping. Restarting at the prior therapeutic dose often causes a "first-dose" nausea response. A two-week microdose bridge (1.0 mg to 1.5 mg) re-establishes tolerance.

Microdosing is inappropriate or counterproductive in these scenarios:

Scenario A: The patient has no nausea history and wants to "play it safe." Starting at 1.0 mg when 2.5 mg would be well-tolerated delays therapeutic effect by four to eight weeks. Weight-loss medications work best when patients see early results; early results improve adherence (Fujioka et al., Obesity 2016). Unnecessary microdosing can paradoxically increase discontinuation by making the first two months feel ineffective.

Scenario B: The patient wants to "stay on a low dose forever" to save money. Maintenance microdosing (staying at 1.0 mg or 1.5 mg indefinitely) is not supported by evidence. The SURMOUNT-4 trial showed that patients who stopped tirzepatide regained weight even after 36 weeks of successful treatment. A sub-therapeutic dose is functionally equivalent to stopping. Patients who cannot afford therapeutic doses should discuss intermittent dosing or alternative medications, not chronic microdosing.

Scenario C: The patient is using microdosing to "avoid side effects entirely." All GLP-1 agonists cause some degree of nausea in the first weeks of treatment. Microdosing reduces intensity but doesn't eliminate it. Patients who are unwilling to tolerate any nausea are poor candidates for GLP-1 therapy regardless of starting dose.

How to calculate microdoses from compounded vials

Microdose calculation follows the same formula as standard dosing: divide the desired dose (in mg) by the vial concentration (in mg/mL) to get the volume in mL, then multiply by 100 to convert to units on a U-100 syringe.

Example 1: You want to draw 1.0 mg from a 10 mg/mL vial.

• 1.0 mg ÷ 10 mg/mL = 0.10 mL
• 0.10 mL × 100 = 10 units

Example 2: You want to draw 0.5 mg from a 5 mg/mL vial.

• 0.5 mg ÷ 5 mg/mL = 0.10 mL
• 0.10 mL × 100 = 10 units

Example 3: You want to draw 1.5 mg from a 20 mg/mL vial.

• 1.5 mg ÷ 20 mg/mL = 0.075 mL
• 0.075 mL × 100 = 7.5 units

The 7.5-unit draw in Example 3 is difficult to read on most U-100 syringes unless you have a 0.3 mL barrel with half-unit markings. If your microdose calculation results in a fractional unit count (2.5 units, 7.5 units, 12.5 units), confirm that your syringe has the precision to draw it. If not, request a different vial concentration from your pharmacy.

A common error: patients calculate the dose in milligrams correctly but forget to check the vial concentration before drawing. If you switch pharmacies or receive a refill at a different concentration, recalculate. The same "10 units" can be 0.5 mg, 1.0 mg, or 2.0 mg depending on the vial.

For a step-by-step drawing protocol with photos, see our how to draw tirzepatide safely guide.

Microdose titration schedules: three common protocols

Compounding providers use three main titration schedules for patients starting below 2.5 mg. None are FDA-approved. All are off-label adaptations.

Protocol 1: Slow titration (12-week ramp)

• Weeks 1-4: 0.5 mg weekly
• Weeks 5-8: 1.0 mg weekly
• Weeks 9-12: 2.0 mg weekly
• Week 13+: 2.5 mg weekly, then standard escalation (5 mg, 7.5 mg, etc.)

This is the most conservative schedule. It's used for patients with severe nausea history or prior GLP-1 intolerance. The downside is that therapeutic dosing doesn't begin until week 13, delaying measurable weight loss by three months.

Protocol 2: Moderate titration (8-week ramp)

• Weeks 1-4: 1.0 mg weekly
• Weeks 5-8: 2.0 mg weekly
• Week 9+: 2.5 mg weekly, then standard escalation

This is the most common microdose protocol in compounding telehealth. It balances tolerability and time to therapeutic effect. Most patients see minimal weight loss in the first eight weeks, then 1-2% body weight loss per month once they reach 5 mg.

Protocol 3: Fast titration (4-week ramp)

• Weeks 1-2: 1.5 mg weekly
• Weeks 3-4: 2.0 mg weekly
• Week 5+: 2.5 mg weekly, then standard escalation

This is used for patients restarting after a gap or patients with mild nausea concern who don't want a prolonged ramp. It's a compromise between starting at 2.5 mg and a full microdose protocol.

When to modify the schedule:

• If nausea is severe (vomiting more than twice in a week, inability to eat), hold at the current dose for an additional two to four weeks before escalating.
• If nausea is absent or mild (queasiness that resolves within 48 hours of injection), you can escalate faster. Some providers skip the 2.0 mg step and go from 1.0 mg to 2.5 mg.
• If weight loss stalls for more than four weeks at a sub-therapeutic dose, escalate even if the original schedule says to wait. Staying at 1.0 mg for 12 weeks because "the plan says so" is not evidence-based.

Storage and administration differences at low doses

Microdoses have the same storage requirements as standard doses (refrigerate at 36-46°F, discard 28 days after first puncture), but three practical differences matter:

Difference 1: Vial longevity. A 30 mg vial at 10 mg/mL (3 mL total volume) contains 30 weekly 1.0 mg doses or 15 weekly 2.0 mg doses. If you're microdosing, a single vial lasts much longer than the 28-day discard window. You'll waste medication. Some compounding pharmacies offer smaller vials (10 mg or 15 mg total) for microdosing patients to reduce waste. Ask when ordering.

Difference 2: Injection volume perception. A 1.0 mg dose at 10 mg/mL is 10 units (0.10 mL), a very small injection volume. Some patients report not "feeling" the injection and worry they missed the subcutaneous space. This is normal. Tirzepatide is injected subcutaneously, not intramuscularly. You don't need to feel resistance. If the syringe empties and you followed correct technique (pinch skin, 90-degree angle, steady plunger push), the dose went in.

Difference 3: Injection site reactions at low doses. Paradoxically, some patients report more injection site redness or itching at microdoses than at standard doses. The likely mechanism is that lower-concentration solutions (5 mg/mL) have more excipient volume per dose, and excipients (mannitol, m-cresol) can cause local irritation. If you have persistent site reactions at microdoses, switching to a higher-concentration vial (20 mg/mL) reduces excipient exposure per injection.

When to move past microdosing

Microdosing is a temporary phase, not a long-term strategy. You should escalate to 2.5 mg or higher once one of three conditions is met:

Condition 1: Nausea has resolved or become manageable. If you've been at 1.0 mg for four weeks and nausea is absent or mild (resolves within 48 hours of injection), escalate. Staying at a sub-therapeutic dose because "it's working fine" delays results. "Working fine" at 1.0 mg usually means you're not hungry for 24 hours post-injection, then appetite returns. That's not therapeutic.

Condition 2: You've completed the planned titration schedule. If your provider prescribed an 8-week microdose ramp, move to 2.5 mg at week 9 even if you feel you "could stay at 2.0 mg longer." The schedule exists to get you to therapeutic dosing in a defined timeframe. Extending microdosing without a clinical reason (persistent severe nausea, vomiting, dehydration) is not appropriate.

Condition 3: Weight loss has stalled for four consecutive weeks. If you've lost 2-3% body weight in the first month of microdosing (common due to initial water weight and appetite suppression), then plateau for four weeks, you've likely hit the ceiling of what that dose can do. Escalate.

The pattern we see most often in patients who "get stuck" microdosing is fear of side effects. They tolerated 1.0 mg well, lost a few pounds, and worry that escalating to 2.5 mg will bring back nausea. In most cases it doesn't. The body has adapted to GLP-1 receptor activation. The jump from 1.0 mg to 2.5 mg is usually smoother than the jump from 0 mg to 1.0 mg.

If you're hesitant to escalate, split the difference: go to 2.0 mg for two weeks, then 2.5 mg. But don't stay at 1.0 mg for six months. That's not treatment, it's avoidance.

FAQ

What is considered a microdose of tirzepatide? Any dose below the FDA-approved starting dose of 2.5 mg weekly. The typical microdose range is 0.5 mg to 2.0 mg, with 1.0 mg being the most common starting point in compounded tirzepatide protocols.

Is microdosing tirzepatide effective for weight loss? Microdoses below 2.5 mg are unlikely to produce significant weight loss on their own. They're used as a temporary titration step to reduce nausea, not as a long-term therapeutic dose. Patients typically need to escalate to 5 mg or higher to see meaningful weight loss.

How long should I stay on a microdose? Two to eight weeks, depending on your titration schedule and side effect tolerance. If nausea is absent or mild after four weeks, escalate to the next dose. Staying on a microdose longer than eight weeks without a clinical reason delays therapeutic effect.

Can I stay on 1.0 mg tirzepatide indefinitely? Not if your goal is weight loss or glucose control. Doses below 2.5 mg are sub-therapeutic for most patients. The SURMOUNT trials showed dose-dependent weight loss, with minimal effect below 5 mg weekly. Chronic microdosing is not a validated maintenance strategy.

What's the smallest tirzepatide dose I can draw accurately? With a U-100 insulin syringe, the practical lower limit is 2.5 units (0.025 mL), which corresponds to 0.5 mg at 20 mg/mL concentration or 0.25 mg at 10 mg/mL. Doses below 2.5 units are difficult to read on standard syringes.

Do microdoses cause fewer side effects? Yes, lower doses generally cause less nausea, but they don't eliminate it. Most patients still experience some queasiness in the first 48 hours after injection, even at 0.5 mg. Microdosing reduces intensity, not incidence.

Should I start with a microdose if I've never used a GLP-1 before? Not necessarily. If you have no history of severe nausea or GI issues, starting at 2.5 mg is appropriate. Microdosing is reserved for patients with known nausea sensitivity or prior GLP-1 intolerance.

How do I calculate a microdose from my vial? Divide the desired dose in milligrams by your vial's concentration in mg/mL to get the volume in mL, then multiply by 100 to convert to units. For example, 1.0 mg from a 10 mg/mL vial is 0.10 mL or 10 units.

Can I split my weekly dose into smaller, more frequent injections? Tirzepatide's half-life is approximately 5 days, designed for weekly dosing. Splitting into twice-weekly or daily injections is off-label and not studied. Some patients do this during titration if side effects are intolerable, but it should be discussed with your provider.

What if I accidentally inject a full 2.5 mg dose when I meant to inject 1.0 mg? Monitor for nausea, vomiting, and abdominal pain over the next 48 hours. Drink plenty of fluids. Most patients tolerate an accidental dose escalation without severe effects, but contact your provider if vomiting is persistent or you can't keep fluids down.

Does insurance cover microdosing? Brand-name tirzepatide (Mounjaro, Zepbound) is only FDA-approved at 2.5 mg and higher, so insurance won't cover off-label microdoses. Compounded tirzepatide is not covered by most insurance regardless of dose. Microdosing is almost exclusively a cash-pay, compounded-medication practice.

Is there a difference between microdosing tirzepatide and semaglutide? Semaglutide's FDA-approved starting dose for weight loss is 0.25 mg (Wegovy), which is already a "microdose" by tirzepatide standards. Tirzepatide's starting dose is 10 times higher (2.5 mg), so the microdosing range is different. Providers sometimes use semaglutide dosing schedules as a template for tirzepatide microdosing, but the two drugs are not interchangeable.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
4. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2023.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Fujioka K et al. Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016.
7. National Community Pharmacists Association. Compounding pharmacy survey: GLP-1 receptor agonist prescribing patterns Q4 2023. 2024.
8. FDA. Mounjaro (tirzepatide) prescribing information. 2022.
9. FDA. Zepbound (tirzepatide) prescribing information. 2023.
10. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
13. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
14. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.